Quantinno Capital Management LP Sells 382,663 Shares of Integra LifeSciences Holdings Corporation $IART

Quantinno Capital Management LP lowered its holdings in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 45.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 459,429 shares of the life sciences company’s stock after selling 382,663 shares during the quarter. Quantinno Capital Management LP’s holdings in Integra LifeSciences were worth $4,328,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Rubric Capital Management LP increased its holdings in Integra LifeSciences by 1.3% in the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock worth $96,304,000 after buying an additional 100,000 shares in the last quarter. Paradigm Capital Management Inc. NY lifted its stake in Integra LifeSciences by 50.6% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock valued at $37,800,000 after acquiring an additional 1,347,700 shares during the period. Invesco Ltd. lifted its stake in Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock valued at $43,754,000 after acquiring an additional 31,931 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after acquiring an additional 267,134 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after acquiring an additional 21,717 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART opened at $17.25 on Friday. The firm has a 50 day moving average of $17.90 and a 200 day moving average of $13.64. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $1.34 billion, a price-to-earnings ratio of -191.65, a price-to-earnings-growth ratio of 1.44 and a beta of 1.21. Integra LifeSciences Holdings Corporation has a 12-month low of $8.70 and a 12-month high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IART shares. Truist Financial boosted their price objective on shares of Integra LifeSciences from $14.00 to $19.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research report on Thursday, June 18th. BMO Capital Markets initiated coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price for the company. UBS Group assumed coverage on Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price target on the stock. Finally, Wells Fargo & Company lifted their price objective on Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $18.86.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.